

# Japan Compounded Sterile Preparations Market - 2024-2033

<https://marketpublishers.com/r/JA03739F1CBCEN.html>

Date: March 2026

Pages: 182

Price: US\$ 2,999.00 (Single User License)

ID: JA03739F1CBCEN

## Abstracts

The Japan Compounded Sterile Preparations Market was valued at US\$ 129 Million in 2024 and is anticipated to reach US\$ 227.37 Million by 2033, at a CAGR of 0.065 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan Compounded Sterile Preparations Market.

This report delivers a comprehensive overview of the Japan Compounded Sterile Preparations Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Compounded Sterile Preparations Market. The Japan Compounded Sterile Preparations Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan Compounded Sterile Preparations Market Scope:

By Dosage Form

Injectables

Infusion Solutions

Ophthalmic Solutions

Topical Sterile Gels & Preparations

#### By Route of Administration

Intravenous (IV)

Intramuscular (IM)

Subcutaneous (SC)

Ocular

#### By Therapeutic

Oncology

Infectious Diseases

Cardiovascular Diseases

Hormonal Therapy

Others

#### By Compound Risk Level

Low-Risk Sterile Compounding

Medium-Risk Sterile Compounding

High-Risk Sterile Compounding

## By End-User

Hospitals

Specialty clinics

Pharmacies

Home Healthcare & Outpatient Settings

## By Compounding Facility Type

Hospital-Based Sterile Compounding Units

Independent Compounding Pharmacies

Outsourcing Sterile Compounding Facilities

## By Preparation Type

Ready-to-Administer (RTA) Preparations

Total Parenteral Nutrition (TPN) Admixtures

Hazardous Drug Compounding

Patient-Specific Customized Doses

## Key Players

Nichi-Iko Pharmaceutical Co., Ltd.

FRESENIUS KABI AG

Astellas Pharma Inc.

Sato Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Chugai Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Baxter International, Inc.

Vetter Pharma-Fertigung GmbH & Co. KG

## Major Highlights

This report delivers a comprehensive overview of the Japan Compounded Sterile Preparations Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Compounded Sterile Preparations Market. The Japan Compounded Sterile Preparations Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia)

Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

#### Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### 1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

### 2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

### 3. DYNAMICS

#### 3.1. Impacting Factors

##### 3.1.1. Drivers

- 3.1.1.1. Strong demand for ready-to-administer (RTA) sterile injectables
- 3.1.1.2. Growth in home infusion and outpatient IV treatments
- 3.1.1.3. Hospital automation and investment in aseptic compounding technology

##### 3.1.2. Restraints

- 3.1.2.1. Strict regulatory compliance requirements increasing approval and audit burden
- 3.1.2.2. Short shelf life of compounded sterile products limiting distribution flexibility

##### 3.1.3. Opportunity

- 3.1.3.1. Strategic outsourcing of sterile compounding by hospitals to specialized providers
- 3.1.3.2. Integration of automation and robotic aseptic compounding systems
- 3.1.3.3. Partnerships with biotech companies for biologics handling and reconstitution

##### 3.1.4. Trends

- 3.1.4.1. Shift toward Ready-to-Administer (RTA) Sterile Products to improve safety

and reduce medication errors

3.1.4.2. Adoption of Automated Aseptic Compounding Systems and robotics

3.1.5. Impact Analysis

## **4. INDUSTRY ANALYSIS**

4.1. Porter's Five Force Analysis – Japan Compounded Sterile Preparations Market

4.2. Geopolitical & Supply Chain Exposure

4.3. Social & Patient-Centric Factors

4.4. Economic Factors

4.5. Pricing Analysis

4.6. Regulatory Analysis

4.7. Go-To-Market (GTM) Strategy

4.8. Innovation & R&D Trends

4.9. Sustainability and ESG Analysis

4.10. Sterile Injectable Generic Participants

4.11. Buyer Decision Criteria & Adoption Drivers

4.12. DMI Opinion – Strategic Outlook for the Japan Compounded Sterile Preparations Market

## **5. BY DOSAGE FORM**

5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form

5.1.2. Market Attractiveness Index, By Dosage Form

5.2. Injectables\*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.3. Infusion Solutions

5.4. Ophthalmic Solutions

5.5. Topical Sterile Gels & Preparations

## **6. BY ROUTE OF ADMINISTRATION**

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

6.1.2. Market Attractiveness Index, By Route of Administration

6.2. Intravenous (IV)\*

- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Intramuscular (IM)
- 6.4. Subcutaneous (SC)
- 6.5. Ocular

## **7. BY THERAPEUTIC**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic
  - 7.1.2. Market Attractiveness Index, By Therapeutic
- 7.2. Oncology\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Infectious Diseases
- 7.4. Cardiovascular Diseases
- 7.5. Hormonal Therapy
- 7.6. Others

## **8. BY COMPOUND RISK LEVEL**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Compound Risk Level
  - 8.1.2. Market Attractiveness Index, By Compound Risk Level
- 8.2. Low-Risk Sterile Compounding\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Medium-Risk Sterile Compounding
- 8.4. High-Risk Sterile Compounding

## **9. BY END-USER**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals\*
  - 9.2.1. Introduction
  - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Specialty clinics

9.4. Pharmacies

9.5. Home Healthcare & Outpatient Settings

## **10. BY COMPOUNDING FACILITY TYPE**

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Compounding Facility Type

10.1.2. Market Attractiveness Index, By Compounding Facility Type

10.2. Hospital-Based Sterile Compounding Units\*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Independent Compounding Pharmacies

10.4. Outsourcing Sterile Compounding Facilities

## **11. BY PREPARATION TYPE**

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Preparation Type

11.1.2. Market Attractiveness Index, By Preparation Type

11.2. Ready-to-Administer (RTA) Preparations\*

11.2.1. Introduction

11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

11.3. Total Parenteral Nutrition (TPN) Admixtures

11.4. Hazardous Drug Compounding

11.5. Patient-Specific Customized Doses

## **12. COMPETITIVE LANDSCAPE ANALYSIS**

12.1. Competitive Scenario

12.2. Market Positioning/Share Analysis

12.3. Mergers and Acquisitions Analysis

12.4. Partner Identification Analysis

12.5. Investment & Funding Landscape

12.6. Strategic Alliances & Innovation Pipelines

## **13. COMPANY PROFILES**

13.1. Nichi-Iko Pharmaceutical Co., Ltd.\*

- 13.1.1. Company Overview
- 13.1.2. Dosage Form Portfolio
- 13.1.3. Revenue Analysis
- 13.1.4. Pricing Analysis
- 13.1.5. SWOT Analysis
- 13.1.6. Recent Developments
  - 13.1.6.1. Major Deals
  - 13.1.6.2. M&A
  - 13.1.6.3. Collaboration
  - 13.1.6.4. Acquisition
  - 13.1.6.5. Joint Ventures
  - 13.1.6.6. Innovations
- 13.1.7. Recent News
  - 13.1.7.1. Events
  - 13.1.7.2. Conferences
  - 13.1.7.3. Symposiums
  - 13.1.7.4. Webinars
- 13.2. FRESENIUS KABI AG
- 13.3. Astellas Pharma Inc.
- 13.4. Sato Pharmaceutical Co., Ltd.
- 13.5. Takeda Pharmaceutical Company Limited
- 13.6. Chugai Pharmaceutical Co., Ltd.
- 13.7. Daiichi Sankyo Company, Limited
- 13.8. Baxter International, Inc.
- 13.9. Fresenius Kabi AG
- 13.10. Vetter Pharma-Fertigung GmbH & Co. KG (LIST NOT EXHAUSTIVE)

## **14. JAPAN COMPOUNDED STERILE PREPARATIONS MARKET – RESEARCH METHODOLOGY**

- 14.1. Research Data
  - 14.1.1. Secondary Data
  - 14.1.2. Primary Data
  - 14.1.3. CAGR Analysis
- 14.2. Market Size Estimation Methodology
  - 14.2.1. Bottom-Up Approach
  - 14.2.2. Top-Down Approach
- 14.3. Market Breakdown & Data Triangulation
- 14.4. Research Assumptions

14.5. Limitations

## **15. APPENDIX**

15.1. About Us and Services

15.2. Contact Us

## I would like to order

Product name: Japan Compounded Sterile Preparations Market - 2024-2033

Product link: <https://marketpublishers.com/r/JA03739F1CBCEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JA03739F1CBCEN.html>